> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide Aims to Expand Non-Animal Methods in Drug Development
- URL: https://www.fdaweb.com/guide-aims-to-expand-non-animal-methods-in-drug-development/
- Published: 2026-03-18T12:00:00.000Z
- Updated: 2026-09-14T13:35:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160838

FDA has issued a draft guidance encouraging drug developers to adopt new approach methodologies (NAMs) as part of a broader effort to reduce reliance on animal testing and improve the prediction of human drug safety. The [document](https://www.fda.gov/media/191589/download?ref=fdaweb.com) outlines a framework for validating these emerging tools, ranging from advanced cell-based assays to computer modeling, when used in regulatory submissions.

NAMs include a wide array of techniques such as in vitro systems, organ-on-a-chip technologies, and *in silico* models. FDA officials say these approaches may offer more human-relevant data than traditional animal studies, particularly in predicting toxicity and understanding mechanisms of action.

The guidance builds on legislative changes enacted in 2022 that clarified non-animal testing methods can be used to support regulatory submissions. While animal studies have historically been the backbone of preclinical safety testing, FDA says it is actively working to integrate alternative methods that can enhance efficiency and potentially improve patient safety.

Importantly, the agency emphasized that NAMs do not need to be fully validated in every case to be considered. Instead, they can be used within a broader “weight of evidence” framework, where multiple data sources are evaluated together. FDA encourages developers to use NAMs that are “fit-for-purpose” — meaning they are appropriate for answering specific scientific or regulatory questions, such as dose selection, toxicity mechanisms, or the need for certain animal studies.

The draft highlights four key principles sponsors should address when validating NAMs:

- **Context of use**: Clearly defining how the method will inform a regulatory decision
- **Human biological relevance**: Demonstrating how well the model reflects human physiology
- **Technical characterization**: Ensuring reliability, reproducibility, and robustness of the method
- **Fit-for-purpose**: Showing the method meaningfully contributes to safety or efficacy assessments

The agency also recommends detailed documentation of study design, statistical methods, assay conditions, and biological variability to build confidence in NAM-derived data. It urges early engagement between sponsors and FDA review divisions when considering NAMs, particularly for complex or novel applications. Developers are also advised to align with international standards, such as those from the Organization for Economic Co-operation and Development, where applicable.